文献速递肝病

原发性胆汁性胆管炎改善生存的治疗目标:目标应为胆红素在正常范围且碱性磷酸酶正常化

Goals of Treatment for Improved Survival in Primary Biliary Cholangitis: Treatment Target Should Be Bilirubin Within the Normal Range and Normalization of Alkaline Phosphatase.
PubMed 文献 · Am J Gastroenterol · 2020-01-01

基于GLOBAL PBC研究组欧洲和北美中心长期随访数据,纳入基线或1年时胆红素≤1倍正常上限的原发性胆汁性胆管炎患者。预测肝移植或死亡的最佳胆红素阈值为0.6倍正常上限(HR 2.12,95%CI 1.69-2.66,P<0.001),胆红素≤0.6倍正常上限与>0.6倍正常上限者10年生存率分别为91.3%和79.2%(P<0.001)。碱性磷酸酶正常化者10年生存率93.2%,高于碱性磷酸酶1.0-1.67倍正常上限者的86.1%。

要点

  • 胆红素≤0.6倍正常上限者10年生存率91.3%,高于>0.6倍正常上限者的79.2%。
  • 碱性磷酸酶≤1倍正常上限者10年生存率93.2%,高于1.0-1.67倍正常上限者的86.1%。
  • 熊去氧胆酸诱导胆红素降至0.6倍正常上限以下与10年生存率改善11%相关。

核心结论

  • 胆红素≤0.6倍正常上限或碱性磷酸酶正常与原发性胆汁性胆管炎患者肝移植或死亡风险最低相关,对治疗目标有重要意义。

研究设计与样本

  • 使用GLOBAL PBC研究组的患者队列,包含欧洲和北美中心的长期随访数据。
  • 纳入基线或1年时胆红素≤1倍正常上限的熊去氧胆酸治疗和未治疗患者。
  • 在1年时碱性磷酸酶≤1.67倍正常上限的亚组中评估碱性磷酸酶正常与无移植生存的关联。
  • 评估预测肝移植或死亡的胆红素和碱性磷酸酶最佳阈值。
  • 时间零点队列2281例患者,1年队列2555例患者。

主要发现

  • 1年时预测肝移植或死亡能力最高的胆红素阈值为0.6倍正常上限(HR 2.12,95%CI 1.69-2.66,P<0.001)。
  • 胆红素≤0.6倍正常上限与>0.6倍正常上限患者的10年生存率分别为91.3%和79.2%(P<0.001)。
  • 胆红素水平低于0.6倍正常上限时肝移植或死亡风险稳定,超过该阈值后风险增加。
  • 熊去氧胆酸诱导胆红素降至该阈值以下与10年生存率改善11%相关。
  • 碱性磷酸酶≤1倍正常上限与1.0-1.67倍正常上限患者的10年生存率分别为93.2%和86.1%。

关键数值与推荐

  • 预测肝移植或死亡的胆红素最佳阈值为0.6倍正常上限(HR 2.12,95%CI 1.69-2.66,P<0.001)。
  • 胆红素≤0.6倍正常上限者10年生存率91.3%,>0.6倍正常上限者79.2%(P<0.001)。
  • 碱性磷酸酶≤1倍正常上限者10年生存率93.2%,碱性磷酸酶1.0-1.67倍正常上限者86.1%。
  • 熊去氧胆酸诱导胆红素降至0.6倍正常上限以下与10年生存率改善11%相关。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: In primary biliary cholangitis (PBC), bilirubin and alkaline phosphatase (ALP) are widely established as independent predictors of prognosis. Current treatment goals do not aim for normalization of surrogate markers because their association with survival has not been defined. METHODS: The patient cohort from the GLOBAL PBC Study Group was used, comprising of long-term follow-up data from European and North American centers. Ursodeoxycholic acid-treated and untreated patients with bilirubin levels ≤1 × upper limit of normal (ULN) at baseline or 1 year were included. The association of normal ALP with transplant-free survival was assessed in a subgroup with ALP ≤1.67 × ULN at 1 year. Optimal thresholds of bilirubin and ALP to predict liver transplantation (LT) or death were evaluated. RESULTS: There were 2,281 patients included in the time zero cohort and 2,555 patients in the 1-year cohort. The bilirubin threshold with the highest ability to predict LT or death at 1 year was 0.6 × ULN (hazard ratio 2.12, 95% CI 1.69-2.66, P < 0.001). The 10-year survival rates of patients with bilirubin ≤0.6 × ULN and >0.6 × ULN were 91.3% and 79.2%, respectively (P < 0.001). The risk for LT or death was stable below the bilirubin levels of 0.6 × ULN, yet increased beyond this threshold. Ursodeoxycholic acid-induced reduction in bilirubin below this threshold was associated with an 11% improvement in 10-year survival. Furthermore, ALP normalization was optimal, with 10-year survival rates of 93.2% in patients with ALP ≤ 1 × ULN and 86.1% in those with ALP 1.0-1.67 × ULN. DISCUSSION: Attaining bilirubin levels ≤0.6 × ULN or normal ALP are associated with the lowest risk for LT or death in patients with PBC. This has important implications for treatment targets.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Murillo Perez CF, Harms MH, Lindor KD, et al. Goals of Treatment for Improved Survival in Primary Biliary Cholangitis: Treatment Target Should Be Bilirubin Within the Normal Range and Normalization of Alkaline Phosphatase. Am J Gastroenterol. 2020. PMID: 32618657. doi:10.14309/ajg.0000000000000557

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。